Compare GSK plc (GSK) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs RLX Technology Inc — how do they compare? GSK plc trades at $52.69 (market cap $101.34B), while RLX Technology Inc trades at $2.03 (market cap $2.46B). The key difference: GSK plc is far larger — about 41.2× RLX Technology Inc's market cap, and RLX Technology Inc pays the higher dividend (4.98%). Which is the better fit depends on your goals.
| GSK | RLX | |
|---|---|---|
Market Cap | $101.34B | $2.46B |
Sector | Health | Technology |
52-Week High | $61.18 | $2.73 |
52-Week Low | $36.20 | $1.79 |
Enterprise Value | $121.95B | $1.09B |
Dividend Yield | 3.49% | 4.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
RLX trades at $2.025, up 2.27% today, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue growth driven by international expansion, though it missed EPS estimates for three consecutive quarters. With a P/E of 18.37 and strong cash flow from operations of $1.10B in 2025, fundamentals show profitability but recent earnings underperformance warrants attention.
The outlook is mixed; RLX operates in a high-growth vaping market projected to reach $462bn by 2033, and it is debt-free with a cash-rich balance sheet. However, risks include regulatory pressures in China and consistent earnings misses. Analyst sentiment is neutral with a single hold rating, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
